Literature DB >> 10188011

Extrapyramidal symptoms and neuropsychological deficits in schizophrenia.

B W Palmer1, R K Heaton, D V Jeste.   

Abstract

BACKGROUND: Extrapyramidal (EP) symptoms and neuropsychological (NP) deficits are both frequently present among schizophrenia patients. EP symptoms, such as motor slowing, could hinder performance on NP tests, yet little is known about the relationship between EP symptoms and NP functioning among schizophrenia patients.
METHODS: Using a comprehensive NP test battery and standard ratings of EP symptoms and other psychiatric characteristics, we conducted a cross-sectional exploration of the association between EP symptoms and NP functioning among 96 middle-aged and elderly outpatients with schizophrenia.
RESULTS: Severity of EP symptoms was associated with worse NP performance, particularly the areas of learning and motor skills. Regression analyses indicated that the relationship between EP symptoms and NP deficits was not accounted for by slowed motor or mental processing, demographic characteristics, severity of psychopathology, dyskinesia, or medication status.
CONCLUSIONS: The pathophysiological mechanisms underlying EP symptoms and some NP deficits in schizophrenia may overlap.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188011     DOI: 10.1016/s0006-3223(98)00167-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  2 in total

1.  Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders.

Authors:  Stéphane Potvin; Ginette Aubin; Emmanuel Stip
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-06-13       Impact factor: 5.270

Review 2.  Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature.

Authors:  Giulia M Giordano; Francesco Brando; Pasquale Pezzella; Maria De Angelis; Armida Mucci; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2022-08-30       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.